PEOPLE - Inovio Biomedical makes appointment:
This article was originally published in Clinica
Selective electrochemical tumour ablation (SECTA) therapy device developer Inovio Biomedical has named Michael Fons as vice-president of corporate development. SECTA is an alternative to localised surgical tumour removal. HTA, markets and IP specialist Dr Fons had been executive director at the San Diego, California company for some three years.
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.